News From SDEE Members

Join us for an enlightening event hosted by Gryphon Online Safety, the San Diego based startup at the forefront of digital safety -- helping parents confidently keep their children safe online. When: June 29 Thursday 6PMWhere: WeWorks LaJollaRSVP on Meetup: https://www.meetup.com/san-diego-technology-startups-meetup-group/events/294094346/Parking validation provided With over 60,000 units already in homes, we're...

The Aquillius Pitch Competition provides the opportunity for founders to showcase their companies and win FREE incubee membership and lab or office space at Aquillius for 1 year. 1 year Aquillius membership for 1 person 1 year Aquillius lab space (one 6-ft lab bench) or 1 year Aquillius office space...

Hello there! Solo technical founder here. I am a former engineer, former local government sustainability planner piloting a community-scale organics waste management solution. My proof-of-concept facility has been successful so far and we're coming out of the R&D phase to lots of different entities interested in partnering.  I am in...

Sublease is available in Sorrento Mesa at <<market rate: fully furnished ~1100 sqft with executive office, large common office area and large room suitable for experimental work and storage; kitchen access optional. Please send inquiries to Reiko Bachand at [email protected].

Experience levels BS with 2 years experience in pharmaceutical lab - HPLC experience is required BS/MS with 5 to 10 years experience in pharmaceutical lab - HPLC and injectable formulation experience is required Please email [email protected] with your resume

In this post, I share a few thoughts about erythropoietic protoporphyria (EPP), a serious debilitating condition for which there are presently no approved treatments. EPP is a rare inherited disorder of heme biosynthesis characterized by dermal photosensitivity secondary to a partial deficiency of ferrochelatase. In a phenotypically similar X-linked protoporphyria (XLP),...

Neuropore announced advancement of UCB0599 to next phase.  UCB0599 is an orally bioavailable, brain barrier penetrant small molecule that prevents the oligomerization of alpha-synuclein. Alpha-synuclein oligomerization and aggregation is implicated in Parkinson’s disease and other degenerative diseases. By inhibiting misfolding and oligomerization of alpha-synuclein, it is believed that the progression...

Neuropore Therapies announced that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34. This Phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics of NPT520-34. NPT520-34 is an orally bioavailable, blood-brain barrier penetrating small molecule. Its mode of action is attenuation of neuroinflammation...

Collidion, Inc. and it’s subsidiaries,  Plex Pharmaceuticals & Avenlogics, Inc has an immediate full-time position open for Pharmaceutical & Medical Device Regulatory Affairs Director. Position: Full-time Location: Flexible To apply, visit www.collidion.com/careers   Founded in 2015, Collidion, Inc. is a private healthcare company with two subsidiaries, Avenlogics, Inc. and Plex...

Plex Pharmaceuticals is interested in sub-leasing 1000-1500 Sq. Ft. of laboratory space on a month-to-month or long-term basis. The sub-lessee will have access to common laboratory equipment, chemical fume hood, tissue culture and other general lab instruments. Lab bench with 3-5 knee holes, dedicated office space, wi-fi, shared conference room,...